Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Anti-CD19 CAR-T in DLBCL
NCT05385263Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Overall Response Rate at 1 month. Status: unknown.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05385263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385263.